Hydrogène de France Announces the World's First Plant for Mass Production of High-Powered Fuel Cells (Over 1 MW)
10.12.2019 23:00:00 EET | Business Wire | Press release
Hydrogène de France (HDF) becomes a French industrial company by launching its high-powered fuel cell production plant in Bordeaux. This plant, with an annual production capacity of 50 MW, will be the first in the world to mass produce high-powered PACs (greater than 1 MW) using PEM (Proton Exchange Membrane) technology. The industrialization and standardization of these systems reduces their cost and improves significantly their reliability and maintenance.
This plant will produce under the brand name "HDF Industry". It will integrate the Fuel Cell stacks of Canadian company Ballard, which today has the most widely deployed technology in the world. This exclusive worldwide agreement allows HDF to offer high-powered FCs whose performance and prices are adapted to the energy market.
A worldwide ambition
HDF intends to play a pioneering role in the emerging hydrogen market. Hydrogen, considered by both industrialists and governments as one of the solutions for the energy transition, is developing in multiple directions, including mobility as well as stationary applications.
HDF's vision is based on the development of hydrogen as a fuel and a vehicle for storing electricity. Renewable energies have conquered a place in the world of energy by overcoming the challenge of competitiveness. HDF believes that the time has come to take on the next challenge, that of intermittency.
An industrial reality
HDF started its industrial program 3 years ago consulting the world's leading fuel cell companies. Ballard was selected as being the ideal partner, as they have demonstrated their experience, industrial capacity and stack lifetime. HDF's industrial plan has been developed with the ClearGen and CEOG projects and with the expertise of its employees.
The HDF Industry plant will have a production capacity of 50MW of Fuel Cell per year within 5 years.
Benefiting from Ballard's know-how and HDF's unique experience in industrial hydrogen projects, this French multimegawatt fuel cell plant has a sizeable lead in the market.
Damien Havard, President and Founder of HDF:
We are particularly pleased with this cooperation with Ballard. HDF industrializes reliable FCs at a price adapted to the market. The standardization of this strategic brick will allow the production of non-polluting and competitive electricity on a large scale. HDF provides the industrial solution that was missing to develop the massive storage of renewable energy. Our market is huge: this is the end of the intermittency of renewable energies!
About Hydrogène de France: industrialist and developer of Renewstable® power plants
A specialist in hydrogen technologies, HDF develops, finances, builds and operates multimegawatt industrial power generation infrastructures.
A pioneer in its sector of activity, HDF achieved a world first in 2019 in Martinique, the ClearGen project: the installation and commissioning of a high-powered fuel cell (1 MW), using the hydrogen co-produced by the SARA refinery by transforming it into electricity. This project is funded by Europe (FCH-JU) and SARA.
HDF marketed the Renewstable® power plants, which capture intermittent renewable energy and store it massively in the form of hydrogen to produce stable, 24-hour electricity that can be controlled like a thermal power plant at a competitive price. The first Renewstable® power plant is developed in French Guiana, in collaboration with the French infrastructure fund Meridiam and SARA: the CEOG power plant is the largest in the world storing massively renewable energy via hydrogen, to produce stable and non-polluting electricity day and night for 10,000 households. CEOG will start its construction site in early 2020 and produce its first electrons in early 2022.
As an international player, HDF Energy currently has around ten Renewstable® projects in the advanced development phase in several countries.
- HDF Energy website: www.hdf-energy.com
- HDF Industry website: www.hdf-industry.com
- CEOG Power Plant Website: www.ceog.fr
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005394/en/
Contact information
Investor and press relations:
- HDF: communication@hdf-energy.com / +33 (0)5 56 77 77 11 11
Agence 914
Salomé EON :
salome@agence914.fr
+33 6 78 86 66 48
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Record Currency Management Participates in Innovative European Bank for Reconstruction and Development (EBRD) -Backed Mongolian Tugrik Transaction19.6.2026 17:53:00 EEST | Press release
Record Currency Management Ltd (RCM), subsidiary of London-listed Record plc (Record Financial Group), is pleased to announce its participation in an innovative local currency bond transaction issued by the European Bank for Reconstruction and Development (EBRD), supporting the development of Mongolia's capital markets while providing institutional investors with access to attractive frontier market opportunities. RCM is the UK currency management arm of Record Financial Group, the London-listed specialist investment group managing USD 115 billion of assets on behalf of institutional clients worldwide. Record's client base comprises pension funds, foundations, sovereign institutions and other asset managers, with whom the Group has built long-standing relationships through its focus on bespoke investment and risk management solutions. Headquartered in London, Record has offices in Hamburg, Zurich, Zug, New York, and Hong Kong. The investment forms part of Record Financial Group's broad
Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 15:29:00 EEST | Press release
Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level
Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom